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Abstract
In an earlier study, we found increased NO production and NO synthase (NOS) expression in renal and vascular tissues of prehypertensive
and adult spontaneously hypertensive rats (SHR). This study was designed to determine the effects of aging and AT-1 receptor blockade
(losartan 30 mg/kg/day beginning at 8 weeks of age) on NO system in this model. Compared to the Wistar Kyoto (WKY) control rats,
untreated SHR showed severe hypertension, elevated urinary NO metabolite (NOm) excretion, marked upregulations of renal and vascular
eNOS and iNOS proteins, normal renal function and heart weight at 9 weeks of age. Hypertension control with either AT-1 receptor or
calcium channel blockade (felodipine 5 mg/kg/day) mitigated upregulation of NOS isoforms in the young SHR. With advanced age (63
weeks), the untreated SHR showed increased proteinuria, renal insufficiency, cardiomegaly, reduced urinary NOm excretion and depressed
renal and vascular NOS protein expressions as compared to the corresponding WKY group. AT-1 receptor blockade prevented proteinuria,
renal insufficiency, cardiomegaly, and renal and vascular NOS deficiency. Thus, in young SHR, hypertension results in compensatory
upregulation of renal and vascular NOS, which can be attenuated by vigorous antihypertensive therapy. With advanced age, untreated SHR
exhibit cardiomegaly, renal dysfunction and marked reductions of eNOS and iNOS compared with the aged WKY rats. Hypertension control
with AT-1 receptor blockade initiated early in the course of the disease prevents target organ damage and preserves renal and vascular NOS.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
In an earlier study, we found marked upregulation of
renal and vascular endothelial (eNOS) and inducible (iNOS)
nitric oxide synthase isoforms in the prehypertensive (4-
week-old) and adult hypertensive (12-week-old) spontane-
ously hypertensive rats (SHR) [1]. These observations were
confirmed by our recent study that revealed pronounced
upregulations of renal, vascular and cardiac eNOS and
iNOS abundance together with upregulation of nNOS
protein abundance in the kidney and brains of adult SHR
at 12 weeks of age [2]. The study further showed significant
amelioration of hypertension (HTN) coupled with the
reversal of the upregulation of NOS isoforms with antiox-
idant therapy in the 12-week-old SHR. These observations
pointed to the contribution of oxidative stress and height-
ened NO inactivation by reactive oxygen species (ROS) in
the pathogenesis of HTN and compensatory upregulation of
NOS isoforms in these animals. The latter supposition was
based on our previous demonstration that NO exerts a
negative feedback regulatory role in NOS expression [3].
Unlike the prehypertensive (4-week-old) and adult hyper-
tensive (12-week-old) SHR, which exhibit upregulation of
NOS [1,4], the immunostainable eNOS is reportedly
decreased in the aorta of aged SHR [5]. The precise reason
for the disparity in NOS isoform expression between the
young and the aged SHR is not clear. However, it could be
due to chronic uncontrolled HTN, which can promote renal
and cardiovascular disease and endothelial dysfunction
[6,7]. In view of these considerations, we hypothesized that
with aging, renal and vascular tissue NOS isoforms may
gradually decline in untreated SHR. We further considered
that long-term control of HTN may mitigate the compensa-
tory upregulation of NOS in the young and the eventual
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decline of NOS with aging in the SHR. We chose an AT-1
receptor blocker to treat HTN in this project because of the
previously demonstrated role of renin–angiotensin system
in the pathogenesis of HTN and progressive renal and
cardiovascular disease in SHR [8–10].
2. Materials and methods
2.1. Animals
Eight week-old male SHR and Wistar Kyoto (WKY) rats
(Harlan Sprague–Dawley, Inc., Indianapolis, IN) were
employed in the study. Animals were provided with stand-
ard rat chow and water ad libitum and were housed in a
temperature-controlled space with 12-h light and dark
cycles. The SHR were randomized into losartan-treated
and untreated groups. The losartan-treated group received
losartan (Merck Pharmaceutical Inc., West Point, PN) 30
mg/kg/day in the drinking water. The untreated SHR and the
normotensive WKY rats received drug-free water. The
selection of the losartan dosage was based on earlier studies
that demonstrated optimal blood pressure control with the
given dosage in SHR [10]. Subgroups of animals were
studied after 1 week (at 9 weeks of age) while the others
were monitored for 55 weeks and studied at 63 weeks of
age.
In an attempt to dissect the effect of hypertension control
from that of AT-1 receptor blockade on NOS expression,
subgroups of young SHR were treated with the long-acting
calcium channel blocker felodipine (5 mg/kg 1 day, Astra
Zeneca, by subcutaneously implanted osmotic pump) to
match the short-term experiment with losartan. The control
group was subjected to sham treatment using vehicle-loaded
pumps. The felodipine dosage chosen for this experiment
was based on our previous studies that showed optimal
blood pressure control at the given amount [11].
Timed urine collections were obtained periodically using
individual metabolic cages. Arterial pressure was deter-
mined by tail plethysmography (Harvard Apparatus, Nat-
ticks, MA) at regular intervals as described in our earlier
studies [1]. At the conclusion of the given observation
periods, animals were anesthetized with phenobarbital (50
mg/kg/i.p.), then euthanized by exsanguination using car-
diac puncture. Kidney and thoracic aorta were immediately
removed, cleaned, frozen in liquid nitrogen and stored at
70 jC until being processed. Serum and urine creatinine
and urine protein contents were measured using routine
laboratory methods. Creatinine clearance was calculated
using the standard equation.
The protocol employed in this study was approved by the
Institutional Animal Care and Use Committee of the Uni-
versity of California, Irvine.
2.2. Measurement of total nitrate and nitrite (NOv)
Urinary NOm was measured by means of the Seivers’
model 270B nitric oxide analyzer (Seivers Instruments, Inc.,
Boulder, CO) as described in our earlier studies [1].
Fig. 1. Systolic arterial pressure measurements obtained during the study
period in the untreated SHR, losartan-treated SHR (S+L) and the WKY
controls. n=6 animal in each group, P<0.001, ANOVA.
Fig. 2. Urinary NOm excretion in the untreated SHR, losartan-treated SHR
and the WKY control rats at 9 weeks of age (upper panel) and 63 weeks of
age (lower panel). n=6 animals in each group, *P<0.01, ANOVA.
N.D. Vaziri et al. / Biochimica et Biophysica Acta 1592 (2002) 153–161154
2.3. Measurements of tissue NOS isoforms
Frozen tissues were processed for determination of
endothelial (eNOS), and inducible (iNOS) NOS proteins
using anti eNOS and iNOS monoclonal antibodies (Trans-
duction Laboratories, Lexington, KY) as described in our
previous studies [1]. Briefly, thoracic aorta and kidney were
homogenized (25% wt/vol) in 10 mmol/l HEPES buffer,
pH 7.4, containing 320 mmol/l sucrose, 1 mmol/l EDTA,
1 mmol/l DTT, 10 mg/ml leupeptin, and 2 mg/ml aprotinin
at 0–4 jC with a tissue grinder. Homogenates were centri-
fuged at 12,000g for 5 min at 4 jC to remove tissue debris
without precipitating plasma membrane fragments. The
supernatant was used for determination of NOS proteins.
Total protein concentration was determined with the use of a
Bio-Rad kit (Bio-Rad Laboratories, Hercules, CA). The
tissue extracts (50 Ag of protein for aorta and 100 Ag protein
for kidney) were size-fractionated on 4–12% Tris–glycine
gel (Novex, Inc., San Diego, CA) at 120 V for 3 h. After
electrophoresis, proteins were transferred onto hybond-ECL
membrane (Amersham Life Science Inc., Arlington Heights,
IL) at 400 mA for 120 min with the Novex transfer system.
In preliminary experiments, we found given protein loads to
be within the linear range of detection for our Western blot
technique. The membrane was prehybridized in 10 Al of
buffer A (10 mmol/l Tris–HCl, pH 7.5, 100 mmol/l NaCl,
0.1% Tween 20, and 10% nonfat milk powder) for 1 h and
then hybridized for an additional 1-h period in the same
buffer containing 10 Al of the given anti-NOS monoclonal
antibody (1:1000). The membrane was then washed for 30
min in a shaking bath, and the wash buffer (buffer Awithout
nonfat milk) was changed every 5 min before 1 h of
incubation in buffer A plus goat anti-mouse IgG/horseradish
peroxidase at the final titer of 1:1000. Experiments were
performed at room temperature. The washes were repeated
before the membrane was developed with a light-emitting
nonradioactive method with the use of ECL Western blot
detection reagent (Amersham Life Science). The mem-
branes were then subjected to autoluminography for 10–
20 s as needed to optimize visualization of the NOS bands.
The autoluminographs were scanned with a laser densitom-
eter (model PD1211, Molecular Dynamics) to determine the
relative optical densities of the bands. In all instances, the
membranes were stained with Ponceau stain, which verified
the uniformity of protein load and transfer efficiency across
the test samples.
Fig. 3. Urinary protein excretion and creatinine clearance in the untreated SHR, losartan-treated SHR and WKY control rats at 9 weeks of age (upper panel) and
63 weeks of age (lower panel). n=6 in each group, *P<0.01, ANOVA.
N.D. Vaziri et al. / Biochimica et Biophysica Acta 1592 (2002) 153–161 155
2.4. Data analysis
Data are expressed as meanFS.D. Analysis of variance
(ANOVA), multiple range test, and Student’s t-test were




Data are shown in Figs. 1–3. The untreated SHR
exhibited a severe progressive HTN during the observation
period. In contrast, arterial pressure remained virtually
unchanged in the WKY group throughout the 55-week
study period. Long-term AT-1 receptor blockade resul-
ted in normalization of blood pressure in the treated SHR
(Fig. 1).
Urinary NOm excretion was significantly greater in the
untreated SHR at 9 weeks of age when compared with that
in the 9-week-old normotensive WKY group. In contrast,
urinary NOm excretion was significantly lower in the
untreated 63-week-old SHR than that found in the corre-
sponding WKY group. AT-1 receptor blockade significantly
attenuated the elevation of urinary NOm excretion in the
young SHR and prevented the reduction in urinary NOm
excretion in the aged SHR (Fig. 2).
Creatinine clearance, urinary protein excretion and car-
diac mass measurements were similar in the three groups at 9
weeks of age. However, creatinine clearance was signifi-
cantly reduced and urinary protein excretion was markedly
increased in the untreated SHR at 63 weeks of age as
compared to the corresponding values in the losartan-treated
Fig. 4. Representative Western blots and group data depicting thoracic aorta eNOS and iNOS protein abundance in the untreated SHR, losartan-treated SHR
and WKY control rats at 9 weeks of age (upper panels) and 63 weeks of age (lower panels). Autoluminography was conducted for 10 and 20 s, respectively, for
the young and old groups in order to optimize visualization of the NOS bands. Thus, relative optical densities of bands in the young group cannot be compared
with those of the old group. n=6 in each group, *P<0.01, ANOVA.
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SHR and the WKY groups. In contrast, creatinine clearance
and urinary protein excretion in the losartan-treated SHR
were similar to those found in the normotensive WKY group
at 63 weeks of age. (Fig. 3) At the conclusion of the study,
the untreated SHR exhibited a significant increase in cardiac
mass (2.3F0.08 g) compared with the WKY controls
(1.8F0.07 g, P<0.05). Long-term AT-1 receptor blockade
prevented cardiac enlargement in the losartan-treated SHR
(1.7F0.09 g).
Short-term administration of felodipine resulted in sig-
nificant amelioration of hypertension in the treated (147F5
mm Hg) compared to untreated young SHR (201F9 mm
Hg, P<0.01). However, felodipine had no significant effect
on blood pressure in the WKY control rats (109F6 vs.
112F7 mm Hg). Short-term therapy with felodipine had no
significant effect on either creatinine clearance, urinary NOm
excretion or urinary protein excretion in either SHR or
WKY control groups (data not shown).
3.2. NOS data
Compared with the WKY control group, the untreated
SHR exhibited a marked upregulation of thoracic aorta and
kidney eNOS and iNOS proteins at 9 weeks of age. In
contrast, eNOS and iNOS protein abundance in the thoracic
aorta and kidney of the untreated 63-week-old SHR were
significantly lower than the corresponding values in the
losartan-treated SHR and the WKY controls. Long-term AT-
Fig. 5. Representative Western blots and group data depicting kidney eNOS and iNOS protein abundance in the untreated SHR, losartan-treated SHR and
WKY control rats at 9 weeks of age (upper panels) and 63 weeks of age (lower panels). Autoluminography was conducted for 10 and 20 s, respectively, for the
young and old groups in order to optimize visualization of the NOS bands. Thus, relative optical densities of bands in the young group cannot be compared
with those of the old group. n=6 in each group, *P<0.05 vs. WKY and SHR+L groups. +P<0.05 vs. WKY group.
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1 receptor blockade with losartan prevented the elevation in
young SHR and the reduction in the aged SHR of the NOS
isoforms in the vascular and renal tissues (Figs. 4 and 5).
Similarly, hypertension control with felodipine attenuated
the upregulation of eNOS and iNOS in the kidney and
eNOS in the aorta in the young SHR. However, the drug had
no effect in the WKY controls (Figs. 6–8).
4. Discussion
In confirmation of our earlier studies [1,4], the young
hypertensive (9-week-old) SHR exhibited marked increases
in urinary NOm excretion and eNOS and iNOS abundance in
the kidney and thoracic aorta. Increased shear stress, cyclic
strain and elevated pressure have been shown to upregulate
eNOS expression and activity in both in vitro and in vivo
systems [12–15]. Thus, the associated HTN in the SHR
may be, in part, responsible for the observed upregulation of
eNOS in the study animals.
In addition, avid inactivation of NO by ROS, known to
occur in SHR [2,16,17], may contribute to upregulation of
eNOS by limiting the availability of biologically active NO
that exerts a negative feedback action on eNOS expression
[2–4,18,19]. In contrast to eNOS, expression of the con-
stitutively expressed iNOS in the vascular tissue is not
directly regulated by baromechanical factors [15], and as
such, upregulation of iNOS in the young SHR may not be
directly related to HTN per se.
AT-1 receptor blockade with losartan ameliorated HTN
and reversed the compensatory upregulation of eNOS and
iNOS in the kidney and vascular tissue of the 9-week-old
SHR. Similarly, hypertension control with calcium channel
blockade abolished the compensatory upregulation of kidney
and aorta eNOS and kidney iNOS in the young SHR. These
observations point to the role of shear stress and elevated
arterial pressure as the dominant cause of the compensatory
upregulation of eNOS in the young SHR. The lack of
discernible change in NOS expression with calcium channel
blockade in the normotensive WKY rats excludes a possible
blood-pressure-unrelated action of this drug. It is of note that
Ang II has been shown to enhance nicotinamide adenine
dinucleotide phosphate (NADH, NADPH) oxidase-depend-
ent production of superoxide in vascular tissue, cultured
vascular smooth muscle cells and cultured endothelial cells
[20–24]. In fact, superoxide production has been shown to
Fig. 6. Representative Western blots and group data depicting aorta eNOS
(upper panel) and iNOS (lower panel) in 9-week-old WKY, untreated SHR
and felodipine-treated (SHR+F) groups. n=6 in each group, *P<0.01 vs.
other groups.
Fig. 7. Representative Western blots and group data depicting renal eNOS
(upper panel) and iNOS (lower panel) in the 9-week-old WKY, untreated
SHR and felodipine-treated SHR (SHR+F) groups. n=6 animals in each
group, *P<0.01 vs. WKY and SHR+F groups.
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increase in the aorta of SHR [25]. Thus, by blocking the
action of Ang II, AT-1 receptor blockade can help to attenuate
ROS-mediated inactivation of NO, and thereby limit the need
for compensatory upregulation of eNOS [3]. Likewise, HTN,
per se, has been shown to raise ROS generation independ-
ently of circulating humoral factors [26]. Irrespective of its
underlying mechanism, oxidative stress can enhance iNOS
expression via activation of nuclear factor Kappa B (NF-KB).
The latter is mediated by glutathione depletion, which facil-
itates serine phosphorylation and degradation of the inhibitor
of NF-KB (IKB) [27]. Thus, reduction of ROS production in
the vascular tissue by lowering blood pressure and/or AT-1
receptor blockade may help to attenuate the associated
upregulation of vascular iNOS. It is of interest that short-
term administration of both calcium channel blocker and AT-
1 receptor blocker restored aorta eNOS expression to near
normal level in the young SHR. However, only AT-1 receptor
blockade significantly lowered aorta iNOS abundance in the
young SHR. This phenomenon may be due to a pressure-
independent effect of AT-1 receptor blockade possibly via
reduction of ROS production.
Despite severe HTN, urinary NOm excretion in the
untreated 63-week-old SHR was significantly lower than
that found in the corresponding WKY group. The reduction
in urinary NOm excretion was coupled with a marked
reduction of both eNOS and iNOS abundance in the kidney
and thoracic aorta of the aged untreated SHR as compared to
the aged WKY group. The reduction of urinary NOm
excretion and tissue NOS isoform expression found in the
untreated aged SHR observed here is consistent with the
earlier study [5] that showed significant reduction of immu-
nostainable eNOS in the endothelial lining of the aorta in
aged SHR. The reduction in NO production, renal and
vascular NOS abundance in the untreated aged SHR is most
likely due to renal and vascular injury associated with long-
standing HTN [9,28]. This viewpoint is supported by recent
Fig. 8. Representative Western blots and group data depicting aorta (left panels) and kidney (right panels) eNOS (upper panels) and iNOS (lower panels) in 9-
week-old untreated (WKY) and felodipine-treated (WKY+F) WKY rats. n=6 animals in each group. No significant difference was found between felodipine-
treated and vehicle-treated WKY rats.
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immunohistologic studies of Zhou et al. [29], who found
that the reduction in renal tissue NOS isoforms in aged SHR
is primarily due to the loss of NOS-bearing structures and
their replacement with fibrotic material.
The reduction in renal and vascular tissue NOS abun-
dance and urinary NOm excretion in the untreated aged SHR
was accompanied by a significant fall in creatinine clearance
and a marked rise in urinary protein excretion. These
findings are consistent with the development of nephrop-
athy, which is a predictable consequence of uncontrolled
chronic HTN in this model [9]. Likewise, the untreated SHR
showed significant cardiomegaly, reflecting the effect of
chronic elevation of left ventricular workload associated
with aging and longstanding HTN as previously shown in
this model [28].
Long term AT-1 receptor blockade prevented the reduc-
tion in urinary NOm excretion and the decline in eNOS and
iNOS protein abundance despite advancing age in the
losartan-treated SHR. This was accompanied by complete
prevention of proteinuria, renal insufficiency and cardiome-
galy. Prevention of long-term renal and cardiac complica-
tions of HTN with AT-1 receptor blockade in SHR shown
here is consistent with the results of numerous earlier studies
that demonstrated renal and cardiovascular protection with
long-term use of different ACE inhibitors or AT-1 receptor
antagonists in this model [8–10].
We used short-term calcium channel blockade to discern
the effect of blood pressure reduction, per se, on renal and
vascular NOS expression and NO production in SHR.
However, we did not study the effect of long-term calcium
channel blockade in SHR. To our knowledge, the effects of
long-term calcium channel blockade on NOS expression,
renal and cardiac function and structure in SHR have not
been examined and await future investigations.
In conclusion, HTN in SHR results in compensatory
upregulation of renal and vascular NO system early in the
course of the disease and progressive renal and cardiovas-
cular injury coupled with NO deficiency during the
advanced stages of the disease. Hypertension control with
long-term AT-1 receptor blockade prevents renal insuffi-
ciency, proteinuria, cardiomegaly and NO deficiency in
SHR.
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